Test Overview
Clinical Utility
Atypical hemolytic uremic syndrome (aHUS) is an inherited or acquired thrombotic microangiopathy (TMA) caused by dysregulated activation of the alternate pathway of the complement system.Factor H (FH) negatively regulates the alternate complement pathway.A loss of FH function by mutation or under the action of an inhibitor (auto-antibody) is associated with the onset of aHUS.The anti-FH antibody assay by ELISA confirms or invalidates a diagnosis of acquired aHUS due to the presence of anti-FH antibodies.
Method
Enzyme-linked immunosorbent assay (ELISA)
Result Included
Factor H Antibodies
Aliases/Synonyms
Anti-Factor H Antibodies; anti-CFH; Complement Factor H Ab
Specimen
Specimen Type
PlasmaContainers
Collection Containers
Blue top (3.2% buffered citrate)
Volume
Sample Volume
2 mL
Minimum Volume
2 mL
Collection & Handling
Handling Information
Prepare platelet-poor plasma and freeze immediately. Store and send frozen.
Stability
| Frozen |
|---|
| Frozen |
Rejection Criteria
| Criteria | Specification |
|---|---|
| Specimen | Serum |
Performance & Interpretation
Turnaround Time
1 month
Results
-
Factor H AntibodiesTiter
Referral Location
Canada
Interface & Setup
HL7 Interface Codes
| Order Code | Result Name | Result Codes | Units |
|---|---|---|---|
| AFHA P | Anti-Factor H | 64717 | titre |
Test Version
Last Updated
2022-12-15